Atara Biotherapeutics (ATRA) AI Stock Analysis

• Market Cap: $76.25M
• Dividend Yield: N/A
• Average Volume (3M): 51.77K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.06
• Revenue Growth: 475.53%
• EPS Growth: 89.94%
• Country: US
• Employees: 153
• Sector: Healthcare
• Sector Strength: 38
• Industry: Biotechnology
• EPS (TTM): 3.50
• Shares Outstanding: 6,795,628
• 10 Day Avg. Volume: 57,553
• 30 Day Avg. Volume: 51,772
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.72
• Enterprise Value/Revenue: 0.66
• Enterprise Value/Gross Profit: 0.82
• Enterprise Value/Ebitda: -22.80
• 1Y Price Target: $17.00
• Price Target Upside: 51.52% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 51 Neutral
• Price Target: $13.00 ▲(15.86% Upside)

The overall stock score of 51 reflects Atara Biotherapeutics' challenging financial situation, mitigated by recent positive corporate developments, such as the BLA resubmission and potential FDA approval. Technical analysis indicates short-term momentum but warns of potential overbought conditions. Valuation concerns persist due to negative earnings and lack of dividends.

Positive Factors

FDA Review

Tab-cel's BLA was accepted by FDA for priority review, with a PDUFA action date viewed as encouraging.

Financial Milestones

Atara will be eligible for a $40M milestone upon tab-cel approval plus double-digits royalty, extending cash runway.

Operational Strategy

Atara is transferring all tab-cel development and manufacturing costs to Pierre Fabre - limiting cash burn.

Negative Factors

Financial Risk

Risks include inability to resubmit the tab-cel BLA in a timely manner, rejection of the tab-cel BLA resubmission by the FDA, and setbacks with other pipeline candidates.

Regulatory Setbacks

Initial BLA was rejected by FDA due to a third-party manufacturing issue, without request for additional clinical data.

Workforce Reductions

Atara announced a reduction in its workforce that will impact approximately 50% of its current employees.

Atara Biotherapeutics Business Overview & Revenue Model

Company Description

Atara Biotherapeutics (ATRA) is a biotechnology company that focuses on developing transformative therapies for patients with serious diseases. The company specializes in allogeneic T-cell immunotherapy, which leverages the power of the immune system to target and eliminate cancerous or diseased cells. Atara's core products include off-the-shelf T-cell therapies designed to treat various cancers and autoimmune conditions. The company operates within the biopharmaceutical sector, striving to advance its proprietary technology platform to address significant unmet medical needs.

How the Company Makes Money

Atara Biotherapeutics generates revenue primarily through partnerships, collaborations, and licensing agreements with other pharmaceutical and biotechnology companies. These partnerships typically involve upfront payments, milestone payments contingent on the achievement of specific development or regulatory goals, and royalties based on product sales. Additionally, Atara may receive funding from grants or government sources to support its research and development efforts. The company focuses on advancing its product candidates through clinical trials to achieve regulatory approval, which would enable it to commercialize its therapies and generate direct sales revenue.

Atara Biotherapeutics Financial Statement Overview

Summary

Atara Biotherapeutics is facing significant financial challenges. Despite some revenue growth, the company remains unprofitable with negative margins and cash flow. The balance sheet shows financial instability with negative equity, suggesting high leverage and risk. Overall, the financial health of the company is concerning, with a need for strategic improvements to achieve sustainability.

Income Statement

Atara Biotherapeutics has shown some improvement in revenue over the years, with a significant increase in TTM compared to previous years. However, the company continues to operate at a loss with negative net profit margins. The gross profit margin is positive, indicating some efficiency in production, but the negative EBIT and EBITDA margins highlight ongoing operational challenges.

Balance Sheet

The balance sheet reveals a concerning financial structure with negative stockholders' equity, indicating more liabilities than assets. The debt-to-equity ratio is not meaningful due to negative equity, and the equity ratio is negative, reflecting financial instability. These factors suggest high financial risk and potential solvency issues.

Cash Flow

The cash flow statement shows consistent negative free cash flow, indicating the company is burning cash. Operating cash flow is negative, and the free cash flow to net income ratio is not favorable. Although there is some cash inflow from financing activities, the overall cash flow position remains weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	199.73M	128.94M	8.57M	63.57M	20.34M	0.00
Gross Profit	160.27M	107.93M	-313.00K	49.01M	8.96M	-9.87M
EBITDA	-5.74M	-75.75M	-266.00M	-213.72M	-331.12M	-296.74M
Net Income	-15.64M	-85.40M	-276.13M	-2.28B	-3.40B	-3.07B
Balance Sheet
Total Assets	62.04M	109.10M	165.50M	376.42M	468.13M	588.12M
Cash, Cash Equivalents and Short-Term Investments	13.84M	42.50M	51.73M	242.82M	371.07M	500.66M
Total Debt	26.71M	43.83M	57.87M	71.70M	28.27M	13.04M
Total Liabilities	117.11M	206.38M	264.74M	249.78M	188.51M	125.78M
Stockholders Equity	-55.07M	-97.28M	-99.23M	126.64M	279.61M	462.34M
Cash Flow
Free Cash Flow	-67.36M	-68.96M	-194.20M	-274.62M	-231.10M	-185.27M
Operating Cash Flow	-67.24M	-68.72M	-192.98M	-270.43M	-220.52M	-180.76M
Investing Cash Flow	11.11M	8.62M	123.87M	202.96M	22.26M	-120.73M
Financing Cash Flow	34.89M	59.28M	2.01M	53.08M	103.94M	427.57M

Atara Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 11.22
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATRA, the sentiment is Positive. The current price of 11.22 is above the 20-day moving average (MA) of 10.87, above the 50-day MA of 9.30, and above the 200-day MA of 9.12, indicating a bullish trend. The MACD of 0.76 indicates Positive momentum. The RSI at 58.13 is Neutral, neither overbought nor oversold. The STOCH value of 24.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ATRA.

Atara Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	60 Neutral	HK$17.54B	4.97	-4.95%	3.61%	9.71%	-38.85%
ATRA	51 Neutral	$76.25M	―	1063.61%	―	475.53%	89.94%
KPTI	45 Neutral	$33.52M	―	41.08%	―	1.19%	61.65%
NRXP	45 Neutral	$51.49M	―	108.28%	―	―	41.01%
LTRN	45 Neutral	$56.08M	―	-75.66%	―	―	-31.16%
XFOR	44 Neutral	$9.32M	0.70	121.75%	―	―	―
HOWL	42 Neutral	$54.30M	―	-82.81%	―	-92.95%	-50.02%

Atara Biotherapeutics Corporate Events

Atara Biotherapeutics Resubmits BLA for Tab-cel to FDA

On July 14, 2025, Atara Biotherapeutics announced the resubmission of its Biologics License Application (BLA) for tabelecleucel (tab-cel®) to the U.S. FDA, aimed at treating Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD). This resubmission follows collaborative efforts with Pierre Fabre Laboratories to address manufacturing observations noted in a previous Complete Response Letter. Approval of the BLA could trigger a $40 million milestone payment from Pierre Fabre Laboratories. Atara is also finalizing the transfer of clinical studies and operational activities related to tab-cel to Pierre Fabre Laboratories, while maintaining sponsorship of the BLA. The company projects that its current financial resources will support operations into the first quarter of 2026, contingent on achieving BLA approval.

The most recent analyst rating on (ATRA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Atara Biotherapeutics stock, see the ATRA Stock Forecast page.

Atara Biotherapeutics Holds Annual Stockholders Meeting

On June 10, 2025, Atara Biotherapeutics held its annual stockholders meeting, where several key decisions were made. The election of directors resulted in the appointment of three nominees to serve until 2028. Additionally, stockholders approved the executive compensation plan and decided to hold annual advisory votes on this matter. Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (ATRA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Atara Biotherapeutics stock, see the ATRA Stock Forecast page.

Atara Biotherapeutics Announces $16M Stock Offering

On May 14, 2024, Atara Biotherapeutics entered into an underwriting agreement with TD Securities (USA) LLC for an underwritten registered direct offering of its common stock and pre-funded warrants, expected to generate approximately $16 million in gross proceeds. The company plans to use the net proceeds to support its biologics license application for tab-cel and for general corporate purposes, with the offering set to close on May 16, 2025.

The most recent analyst rating on (ATRA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Atara Biotherapeutics stock, see the ATRA Stock Forecast page.

Atara Biotherapeutics Appoints New Board Members Amid Restructuring

On May 14, 2025, Atara Biotherapeutics announced the appointment of James Huang and Nachi Subramanian to its Board of Directors following a direct offering of shares and warrants to institutional investors, expected to close on May 16, 2025. The company aims to extend its cash runway through the first quarter of 2026 with the $16 million proceeds, supporting its ongoing activities for potential BLA approval. Atara has transferred manufacturing responsibilities to Pierre Fabre Laboratories, significantly reducing operating expenses, and has paused its CAR T programs while undergoing organizational restructuring, including a 30% workforce reduction.

The most recent analyst rating on (ATRA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Atara Biotherapeutics stock, see the ATRA Stock Forecast page.

Atara Biotherapeutics Announces Major Workforce Reduction

On May 12, 2025, Atara Biotherapeutics, Inc. announced a significant workforce reduction, affecting approximately 30% of its employees, with the aim of retaining around 23 essential staff members to focus on strategic priorities. The company anticipates completing this reduction by August 2025, incurring approximately $1.4 million in severance and related benefits, primarily as one-time cash charges, with further details to be disclosed in their upcoming quarterly report.

The most recent analyst rating on (ATRA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Atara Biotherapeutics stock, see the ATRA Stock Forecast page.

FDA Lifts Hold on Atara’s EBVALLO Program

On May 5, 2025, Atara Biotherapeutics announced that the FDA lifted the clinical hold on its EBVALLO™ (tabelecleucel) program, initially placed in January 2025 due to GMP compliance issues at a third-party manufacturing facility. This decision allows Atara to resume its Phase 3 ALLELE clinical study and a Phase 2 label-expansion study for patients with EBV-associated post-transplant lymphoproliferative disease. Additionally, the FDA granted a Type A meeting to discuss the path forward for resubmitting the Biologics License Application (BLA) for EBVALLO™. Atara has temporarily paused its strategic option evaluation pending clarity on the BLA resubmission timeline.